Mostrando 2 resultados de: 2
Origen
scopus(2)
Bone-targeted therapy in castration-resistant prostate cancer: Where do we stand?
ReviewAbstract: Introduction: In the last years, there have been significant developments in the therapeutic armamenPalabras claves:Denosumab, prostatic neoplasms, Radium-223, theranostic nanomedicine, Zoledronic acidAutores:Alvarez-Maestro M., Cathelineau X., Debruyne F., Diego M. Carrión, Lorenzo G.D., Maio M.D., Martinez-Piñéiro L., Paul A., Rivas J.G., Saad F., Sanchez-Salas R., Sartor O.Fuentes:scopusA DREAM challenge to build pbkp_rediction models for short-term discontinuation of docetaxel in metastatic castration- resistant prostate cancer
ArticleAbstract: Purpose Docetaxel has a demonstrated survival benefit for patients with metastatic castration-resistPalabras claves:Autores:Abdallah K., Airola A., Aittokallio T., Anghel C., Ankerst D.P., Azima H., Baertsch R., Ballester P.J., Bare C., Bhandari V., Bot B.M., Buchardt A.S., Buturovic L., Cao D., Chalise P., Chang B.H.W., Cho J., Chu T.M., Conjeti S., Correia S., Costello J.C., Dai J., Dai Z., Dang C.C., Dargatz P., Delavarkhan S., Deng D., Dhanik A., Du Y., Elangovan A., Ellis S., Elo L.L., Espiritu S.M., Fan F., Farshi A.B., Freitas A., Fridley B., Fuchs C., Gofer E., Golińska A.K., Graw S., Greiner R., Guinney J., Guo J., Gupta P., Guyer A.I., Han J., Hansen N.R., Hirvonen O., Huang B., Huang C., Hwang J., Ibrahim J.G., Jayaswal V., Jeon J., Ji Z., Juvvadi D., Jyrkkiö S., Kanigel-Winner K., Katouzian A., Kazanov M.D., Khan S.A., Khayyer S., Kim D., Koestler D.C., Kokowicz F., Kondofersky I., Krstajic D., Kumar L., Kurz C., Kyan M., Laajala T.D., Laimighofer M., Lee E., Lesiński W., Li M., Li Y., Lian Q., Liang X., Lim M., Neto E.C., Persona C., Piccolo S.R., Roberto Vega, Ryan C.J., Sartor O., Scher H.I., Seyednasrollah F., Shen L., Soule H.R., Stolovitzky G., Sweeney C.J., Wang T., Winner K.K., Wolfinger R.D., Yates Coley R., Yu T., Zhou F.L.Fuentes:scopus